Intellia Therapeutics Inc’s recent filing unveils that its EVP, Chief Technical Officer Clark Eliana unloaded Company’s shares for reported $6104.0 on Mar 04 ’25. In the deal valued at $8.99 per share,679 shares were sold. As a result of this transaction, Clark Eliana now holds 95,369 shares worth roughly $0.79 million.
Then, BASTA JAMES sold 2,572 shares, generating $23,122 in total proceeds. Upon selling the shares at $8.99, the EVP, General Counsel now owns 111,925 shares.
Before that, Bhanji Muna sold 265 shares. Intellia Therapeutics Inc shares valued at $2,642 were divested by the Director at a price of $9.97 per share. As a result of the transaction, Bhanji Muna now holds 19,468 shares, worth roughly $0.16 million.
Wolfe Research upgraded its Intellia Therapeutics Inc [NTLA] rating to an Outperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. JP Morgan also remained covering NTLA and has decreased its forecast on February 28, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on February 28, 2025. It rated NTLA as “a Sell” which previously was an “a Neutral”.
Price Performance Review of NTLA
On Tuesday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock jump 4.92% to $8.31. Over the last five days, the stock has gained 10.80%. Intellia Therapeutics Inc shares have fallen nearly -28.73% since the year began. Nevertheless, the stocks have fallen -61.02% over the past one year. While a 52-week high of $28.18 was reached on 01/07/25, a 52-week low of $5.90 was recorded on 04/07/25. SMA at 50 days reached $8.96, while 200 days put it at $15.60.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 8.00, which if violated will result in even more drops to 7.70. On the upside, there is a resistance level at 8.47. A further resistance level may holdings at 8.64. The Relative Strength Index (RSI) on the 14-day chart is 53.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 0.82%. Stochastics %K at 83.74% indicates the stock is a selling.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-03-31, growing by 0.9 million shares to a total of 26.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 26.04 million shares. There was a rise of 3.35%, which implies that there is a positive sentiment for the stock.
